share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4:持股变动声明
美股SEC公告 ·  2024/03/27 18:10

Moomoo AI 已提取核心信息

Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
阿迪尔制药公司(ADIL)首席执行官克莱伯恩·卡里·J于2024年3月25日参与了一项涉及该公司股票的交易。不幸的是,该公告没有提供有关交易的股票数量、股票性质、交易价格或交易总价值的详细信息。此外,Claiborne Cary J在交易后持有的股票数量没有披露。建议投资者寻求更多信息,以充分了解这一事件对其投资决策的影响。
阿迪尔制药公司(ADIL)首席执行官克莱伯恩·卡里·J于2024年3月25日参与了一项涉及该公司股票的交易。不幸的是,该公告没有提供有关交易的股票数量、股票性质、交易价格或交易总价值的详细信息。此外,Claiborne Cary J在交易后持有的股票数量没有披露。建议投资者寻求更多信息,以充分了解这一事件对其投资决策的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息